Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy

BACKGROUND: PD-L1 is one of the major immune checkpoints which limits the effectiveness of antitumor immunity. Blockade of PD-L1/PD-1 has been a major improvement in the treatment of certain cancers, however, the response rate to checkpoint blockade remains low suggesting a need for new therapies. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Munoz, Luis Enrique, Huang, Lei, Bommireddy, Ramireddy, Sharma, Richa, Monterroza, Lenore, Guin, Rohini N., Samaranayake, Sarah G., Pack, Christopher D., Ramachandiran, Sampath, Reddy, Shaker J.C., Shanmugam, Mala, Selvaraj, Periasamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611422/
https://www.ncbi.nlm.nih.gov/pubmed/34815353
http://dx.doi.org/10.1136/jitc-2021-002614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611422/
https://www.ncbi.nlm.nih.gov/pubmed/34815353
http://dx.doi.org/10.1136/jitc-2021-002614

Ejemplares similares